Last Updated: 2026-03-13 PT
Huntington's disease (HD) is characterized by remarkable selective vulnerability of the striatum, particularly the medium spiny neurons (MSNs). Despite ubiquitous expression of the mutant huntingtin (mHTT) protein throughout the brain and body, the striatum—particularly the caudate nucleus and putamen—undergoes progressive degeneration far earlier and more severely than other regions [1][2]. Understanding this selective vulnerability is critical for developing targeted neuroprotective therapies.
The striatum is the largest component of the basal ganglia, composed of:
These structures are collectively termed the corpus striatum due to their striped appearance from striosomes and matrix compartments [3].
The striatum contains several neuronal populations:
| Cell Type | Percentage | Vulnerability |
|---|---|---|
| D1-MSNs (direct pathway) | ~50% | High |
| D2-MSNs (indirect pathway) | ~50% | High |
| Cholinergic interneurons | ~1-2% | Relatively spared |
| GABAergic interneurons | ~5% | Variable |
| Parvalbumin+ interneurons | ~1% | Relatively spared |
The striatum is organized into two main compartments:
Striosomes show earlier pathology in HD and may represent "hotspots" of vulnerability [4].
The selective vulnerability of MSNs arises from a convergence of factors:
MSNs show early and profound transcriptional changes in HD, including:
MSNs have high metabolic demands due to:
The mitochondrial dysfunction in HD particularly impacts these energy-demanding cells [6].
MSNs exhibit:
Critical proteins like BDNF require axonal transport from cortex to striatum. mHTT disrupts:
Corticostriatal glutamatergic inputs become overactive in HD, leading to:
Single-nucleus RNA sequencing studies have identified distinct transcriptional signatures in vulnerable MSNs:
| Pathway | Direction | Functional Impact |
|---|---|---|
| Dopamine signaling | ↓ | Motor dysfunction |
| cAMP/PKA signaling | ↓ | Synaptic plasticity loss |
| Mitochondrial function | ↓ | Energy deficit |
| Calcium signaling | ↑ | Excitotoxicity risk |
| Neuroinflammation | ↑ | Glial activation |
| Autophagy | ↓ | Protein clearance failure |
D1-MSNs and D2-MSNs show differential vulnerability patterns:
The striatum receives massive glutamatergic input from:
This convergent excitatory input becomes pathological in HD, with cortical hyperactivity driving striatal excitotoxicity [11].
###Nigrostriatal Dopaminergic Inputs
MSNs project to:
Loss of these outputs disrupts basal ganglia motor control.
Understanding selective vulnerability opens therapeutic avenues:
| Approach | Target | Status |
|---|---|---|
| Creatine supplementation | Energy metabolism | Phase III [14] |
| CoQ10 | Mitochondrial function | Phase III |
| Minocycline | Microglial activation | Phase II/III |
| Amitifadine | Triple reuptake inhibitor | Phase II |
Rationale combinations may prove most effective:
Single-nucleus atlas of HD striatum (2026): Comprehensive cell-type-resolved transcriptomic mapping reveals MSN subpopulation-specific vulnerability signatures [16]
Striosome-targeted therapeutics (2025): Novel approaches to target striosome-specific pathology using engineered viral vectors [17]
Energy metabolism interventions (2025): Triheptanoin supplementation shows promise in early HD patients for improving brain energy metabolism [18]
mHTT propagation mechanisms (2025): Prion-like spread of mHTT aggregates along neuronal connections contributes to propagation of pathology [19]
Glial contributions (2025): Astrocyte and microglia interactions with vulnerable MSNs reveal novel therapeutic targets [20]
Vonsattel & DiFiglia (1998). Huntington disease. Journal of Neuropathology & Experimental Neurology. 1998. ↩︎
Ferrante et al. (1991). Selective sparing in Huntington's disease. Journal of Comparative Neurology. 1991. ↩︎
Graybiel & Ragsdale (1978). Histochemically distinct compartments in the striatum. Science. 1978. ↩︎
Tappe et al. (2022). Striosome pathology in Huntington's disease. Progress in Neurobiology. 2022. ↩︎
Desplats et al. (2021). Transcriptional dysregulation in HD striatum. Nature Neuroscience. 2021. ↩︎
Browne et al. (1999). Mitochondrial dysfunction in Huntington's disease. Annals of Neurology. 1999. ↩︎
Bezprozvanny (2009). Calcium signaling and neurodegenerative diseases. Cell Calcium. 2009. ↩︎
Gunawardena et al. (2003). Disrupted axonal transport in HD. Neuron. 2003. ↩︎
Cepeda et al. (2007). Corticostriatal synaptic dysfunction in HD. Experimental Neurology. 2007. ↩︎
Day et al. (2006). Differential D1/D2 MSN vulnerability in HD. Journal of Neuroscience. 2006. ↩︎
rossi et al. (2024). Cortical hyperactivity in HD mouse models. Brain. 2024. ↩︎
Weeks et al. (2024). Dopaminergic dysfunction in HD. Movement Disorders. 2024. ↩︎
Leavitt et al. (2025). Gene therapy approaches for Huntington's disease. Nature Reviews Neurology. 2025. ↩︎
Hersch et al. '(2023). Creatine in Huntington''s disease: 3-Trial analysis. Neurology'. 2023. ↩︎
Rosser et al. (2024). Cell replacement therapy for HD. Cell Stem Cell. 2024. ↩︎
Lee et al. (2026). Single-nucleus atlas of HD striatum. Cell. 2026. ↩︎
Chen et al. (2025). Striosome-targeted therapeutics. Science Translational Medicine. 2025. ↩︎
Adanyeguh et al. (2025). Triheptanoin in early HD. Annals of Neurology. 2025. ↩︎
Frost et al. (2025). mHTT propagation mechanisms. Nature Neuroscience. 2025. ↩︎
Scialo et al. (2025). Glial contributions to MSN vulnerability. Glia. 2025. ↩︎